Chagas Disease Prevalence Across U.S. States
The Centers for Disease Control and Prevention estimates that over 300,000 people in the United States live with Chagas disease, with the highest concentrations of chronic cases historically linked to vector-borne transmission in the southern tier of states. The CDC's parasitic disease diagnostic resources provide detailed maps and seroprevalence data for healthcare providers, available at CDC Chagas Disease Page. Texas consistently ranks first in reported acute and chronic cases, followed by California, Florida, and New York, reflecting both vector presence and populations from endemic regions.
Seroprevalence studies in blood donor populations, as reported by the American Red Cross and research published in the Morbidity and Mortality Weekly Report, reveal that states along the Gulf Coast and in the Southwest have the highest rates of Trypanosoma cruzi antibodies. The kissing bug vector, known scientifically as triatomine bugs, is established in at least 27 states, with the highest documented vector infection rates in Texas, Arizona, and New Mexico. The CDC's vector-borne disease tracking system offers the latest county-level data on triatomine species and infection rates at CDC Vector-Borne Diseases.
Chagas Disease Transmission and Public Health Infrastructure
Chagas disease states transmission occurs primarily through contact with triatomine bug feces, but also via congenital transmission, blood transfusion, organ transplantation, and rarely through contaminated food or beverages. The FDA has implemented screening protocols for blood donors and organ donors since 2007, significantly reducing transfusion-related cases. The American Association of Blood Banks reports that all 50 states now test donor blood for T. cruzi antibodies, with positive units flagged and removed from the supply.
Congenital transmission, where an infected mother passes the parasite to her baby during pregnancy, is a growing focus of public health programs. The CDC recommends testing for all babies born to mothers with Chagas disease, and untreated congenital infections can lead to severe cardiac and digestive complications decades later. The World Health Organization's roadmap for neglected tropical diseases, which includes Chagas disease, targets elimination of transmission through blood transfusion and congenital routes by 2030, with resources at WHO Chagas Disease.
Economic and Healthcare Burden of Chagas Disease in the U.S.
The economic burden of Chagas disease in the United States is substantial, with annual costs for hospitalization, cardiac care, and lost productivity estimated in the hundreds of millions of dollars. A study published in the journal Emerging Infectious Diseases calculated the lifetime cost per patient with Chagas cardiomyopathy, highlighting the financial strain on Medicaid and private insurers. The CDC's health economics program tracks these costs to guide resource allocation for screening and treatment programs.
Treatment with antiparasitic drugs benznidazole and nifurtimox is most effective in the acute phase, but access and prescribing remain limited in many states. The FDA approved benznidazole for pediatric Chagas disease patients aged 2 to 12 years in 2017, with the manufacturer Chemo Group distributing the drug through the CDC's drug assistance program. Healthcare costs for chronic Chagas cardiomyopathy, including heart transplants, can exceed $1 million per patient over a lifetime, underscoring the need for early detection and expanded state-level public health initiatives, as detailed in the CDC's Chagas disease treatment guidelines at CDC Chagas Treatment.